Daptomycin Hikma

What Is Daptomycin Hikma and What Is It Used For?

Daptomycin Hikma is a cyclic lipopeptide antibiotic administered intravenously to treat serious infections caused by Gram-positive bacteria, including MRSA. It is approved for complicated skin and soft tissue infections in adults and children aged 1 year and older, and for Staphylococcus aureus bacteremia (bloodstream infection) including right-sided infective endocarditis in adults.

Daptomycin belongs to a unique class of antibiotics known as cyclic lipopeptides. It was originally derived from the soil organism Streptomyces roseosporus and has a distinctive mechanism of action that differs from all other antibiotic classes. This makes it particularly valuable in the fight against antibiotic-resistant bacteria, as cross-resistance with other antibiotic classes is uncommon.

The drug works by binding to the bacterial cell membrane in a calcium-dependent manner. Once bound, it inserts into the membrane and forms ion-conducting channels that cause rapid depolarization of the membrane potential. This loss of membrane potential leads to inhibition of protein, DNA, and RNA synthesis, ultimately resulting in bacterial cell death. Importantly, daptomycin is bactericidal, meaning it directly kills bacteria rather than merely inhibiting their growth.

Daptomycin Hikma is specifically indicated for the following conditions:

• Complicated skin and soft tissue infections (cSSTI) in adults and children aged 1 year and older, caused by susceptible Gram-positive organisms including MRSA, Streptococcus pyogenes, Streptococcus agalactiae, and Streptococcus dysgalactiae
• Staphylococcus aureus bacteremia (SAB) in adults, including bloodstream infections associated with right-sided infective endocarditis or complicated skin infections

One of the most clinically important features of daptomycin is its reliable activity against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA), and many vancomycin-resistant enterococci (VRE). This broad Gram-positive coverage makes it a critical tool in modern infectious disease management, particularly in hospital settings where resistant organisms are prevalent.

Pharmacokinetics

Daptomycin exhibits linear pharmacokinetics at doses up to 12 mg/kg administered as a single daily intravenous dose. Steady-state concentrations are achieved by the third daily dose. The drug is approximately 90-93% bound to plasma proteins, primarily albumin. It is primarily excreted by the kidneys, with approximately 78% of the administered dose recovered in urine. The elimination half-life is approximately 8-9 hours in patients with normal renal function, which supports once-daily dosing.

Daptomycin penetrates well into skin blister fluid, achieving concentrations sufficient for antibacterial activity. However, as noted, it does not achieve effective concentrations in the lungs due to inactivation by surfactant. It also has limited penetration into the cerebrospinal fluid, although there are case reports of successful use in central nervous system infections.

What Should You Know Before Taking Daptomycin Hikma?

Before starting daptomycin treatment, your doctor needs to assess your kidney function, baseline CPK levels, and current medications. Daptomycin is contraindicated in patients with known hypersensitivity to the drug and requires careful monitoring throughout treatment.

Contraindications

Daptomycin Hikma must not be used in patients with a known hypersensitivity to daptomycin or any of the excipients. Although true allergic reactions to daptomycin are rare, anaphylaxis has been reported. If a serious allergic reaction occurs during infusion, treatment must be discontinued immediately and appropriate emergency measures initiated.

Daptomycin should not be used for the treatment of pneumonia or any pulmonary infection due to its inactivation by pulmonary surfactant. This is not simply a matter of reduced efficacy — clinical trial data showed significantly worse outcomes in pneumonia patients treated with daptomycin compared to standard therapy.

Warnings and Precautions

Several important precautions must be observed during daptomycin therapy:

Skeletal muscle effects: Daptomycin can cause elevations in creatine phosphokinase (CPK) and, in rare cases, rhabdomyolysis. CPK levels should be measured at baseline and at regular intervals during treatment (at least weekly). Patients should be monitored for signs and symptoms of myopathy, including unexplained muscle pain, tenderness, or weakness. Treatment should be discontinued if CPK rises above 5 times the upper limit of normal (ULN) with symptoms of myopathy, or above 10 times ULN without symptoms.

Peripheral neuropathy: Cases of peripheral neuropathy have been reported during daptomycin treatment. Patients should be monitored for signs of neuropathy, and alternative therapy should be considered if neuropathy develops.

Eosinophilic pneumonia: Cases of eosinophilic pneumonia have been reported in patients receiving daptomycin. Patients who develop fever, dyspnea with hypoxic respiratory insufficiency, and diffuse pulmonary infiltrates should be investigated for this condition. If eosinophilic pneumonia is confirmed, daptomycin should be discontinued and treatment with systemic corticosteroids initiated.

Renal impairment: Since daptomycin is primarily excreted by the kidneys, dose adjustment is necessary in patients with severe renal impairment (creatinine clearance <30 mL/min), including those receiving hemodialysis or continuous ambulatory peritoneal dialysis (CAPD). Renal function should be monitored regularly during treatment.

Drug-laboratory interactions: Daptomycin can cause false prolongation of prothrombin time (PT) and elevation of International Normalized Ratio (INR) when certain recombinant thromboplastin reagents are used. If unexplained elevations in PT/INR are observed, the possibility of this laboratory interaction should be considered.

Pregnancy and Breastfeeding

There are limited data on the use of daptomycin in pregnant women. Animal reproduction studies have not demonstrated clear evidence of harm to the fetus; however, as with all medications, daptomycin should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. The decision to use daptomycin in pregnancy should be made on a case-by-case basis, weighing the severity of the infection against the potential risks.

It is not known whether daptomycin is excreted in human breast milk. Because many drugs are excreted in breast milk, and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the drug to the mother. The European Medicines Agency (EMA) recommends that breastfeeding be discontinued during daptomycin treatment.

Fertility: Animal studies have not shown adverse effects on fertility. No human fertility data are available.

How Does Daptomycin Hikma Interact with Other Drugs?

Daptomycin has relatively few drug interactions compared to many other antibiotics, but caution is needed with HMG-CoA reductase inhibitors (statins) due to increased risk of myopathy, and with other medications that can affect CPK levels or renal function.

Although the number of known drug interactions with daptomycin is relatively limited, certain combinations require careful consideration. The most clinically significant interaction involves HMG-CoA reductase inhibitors (statins), which are among the most widely prescribed medications worldwide. Both daptomycin and statins can independently cause muscle toxicity, and the combination may increase this risk.

Clinical pharmacology studies have shown that daptomycin does not inhibit or induce the cytochrome P450 (CYP) enzyme system. Specifically, it does not affect CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4. This favorable pharmacokinetic profile means that daptomycin is unlikely to alter the metabolism of other drugs processed through these pathways, reducing the potential for many drug-drug interactions.

Major Interactions

The most clinically significant drug interaction with daptomycin involves HMG-CoA reductase inhibitors (statins) such as atorvastatin, simvastatin, rosuvastatin, and others. Both daptomycin and statins can independently cause elevations in CPK and skeletal muscle damage. When used together, the risk of myopathy and potentially rhabdomyolysis may be increased. Guidelines recommend considering temporary suspension of statin therapy during the course of daptomycin treatment. If co-administration is deemed clinically necessary, CPK should be monitored more frequently than weekly (e.g., every 2-3 days), and patients should be closely observed for any signs of muscle pain, tenderness, or weakness.

Minor Interactions

Daptomycin has been studied in combination with several other commonly used antimicrobials, including aztreonam, tobramycin, and probenecid. In these studies, no clinically significant pharmacokinetic interactions were observed. The combination of daptomycin with other antibiotics — particularly beta-lactams — is increasingly being explored in clinical practice as a strategy to enhance bactericidal activity, especially against daptomycin-nonsusceptible organisms. However, these combinations should only be used under specialist guidance.

What Is the Correct Dosage of Daptomycin Hikma?

The standard adult dose of daptomycin is 4 mg/kg once daily for complicated skin infections and 6 mg/kg once daily for S. aureus bacteremia/endocarditis, administered intravenously over 30 minutes or as a 2-minute injection. Dose adjustment is required for patients with severe renal impairment.

Daptomycin dosing is weight-based and varies according to the indication being treated, the patient's age, and their renal function. The drug is always administered intravenously, either as an infusion over 30 minutes using 0.9% sodium chloride solution, or as a slow intravenous injection over 2 minutes. The choice between infusion and injection is generally a matter of clinical preference and institutional protocol.

Adults

Children (1 to 17 years)

Daptomycin is approved for cSSTI in pediatric patients aged 1 year and older. Dosing varies by age group because of differences in pharmacokinetics:

Higher mg/kg doses are required in younger children because daptomycin clearance is faster in this age group. Children aged 1-6 years also require a longer infusion time of 60 minutes compared to 30 minutes for older children and adults. Daptomycin is not approved for bacteremia or endocarditis in pediatric patients, and should not be used in children under 1 year of age.

Elderly

No specific dose adjustment is required for elderly patients based on age alone. However, elderly patients are more likely to have reduced renal function, and dose adjustment based on creatinine clearance may be necessary. Additionally, elderly patients may be more susceptible to myopathy, so careful monitoring of CPK levels is particularly important in this population.

Dose Adjustment in Renal Impairment

For patients with severe renal impairment (creatinine clearance <30 mL/min), including those on hemodialysis or CAPD, the dosing interval is extended:

• cSSTI: 4 mg/kg once every 48 hours
• SAB/endocarditis: 6 mg/kg once every 48 hours

For patients on hemodialysis, daptomycin should preferably be administered after the dialysis session on dialysis days. No dose adjustment is needed for patients with mild to moderate renal impairment (creatinine clearance ≥30 mL/min).

Missed Dose

If a dose of daptomycin is missed, it should be administered as soon as possible. However, if the next scheduled dose is due within a few hours, the missed dose should be skipped and the regular dosing schedule resumed. Doses should never be doubled to make up for a missed dose. As daptomycin is administered in a clinical setting, missed doses are generally uncommon.

Overdose

In the event of an overdose, supportive care is recommended. Daptomycin is slowly cleared by hemodialysis (approximately 15% removed over 4 hours) and by peritoneal dialysis (approximately 11% removed over 48 hours). In cases of significant overdose, monitoring of CPK levels is essential, and patients should be closely observed for signs and symptoms of adverse reactions, particularly myopathy. There is no specific antidote for daptomycin overdose.

What Are the Side Effects of Daptomycin Hikma?

The most commonly reported side effects of daptomycin include fungal infections (candidiasis), urinary tract infections, headache, nausea, vomiting, diarrhea, rash, injection site reactions, and elevated CPK levels. Most side effects are mild to moderate, but serious reactions such as myopathy, eosinophilic pneumonia, and anaphylaxis can occur rarely.

Like all antibiotics, daptomycin can cause side effects, although not everyone will experience them. The side effect profile has been well characterized through clinical trials involving thousands of patients and through post-marketing surveillance. Understanding the frequency and nature of these side effects is important for monitoring during treatment and for recognizing when medical intervention may be needed.

Side effects are classified below according to their frequency. These frequency categories are based on clinical trial data and are standard across all European medicines:

Muscle-Related Side Effects (CPK Elevation)

The most clinically important class-specific side effect of daptomycin is skeletal muscle toxicity. Elevations in creatine phosphokinase (CPK) can occur at any point during treatment but are more likely with higher doses, longer treatment durations, and in patients with pre-existing renal impairment. In clinical trials, CPK elevations above 5 times the upper limit of normal occurred in approximately 2.8% of patients receiving daptomycin 4 mg/kg and 8.9% of patients receiving 6 mg/kg. Most CPK elevations resolve after discontinuation of therapy.

To mitigate this risk, CPK levels should be measured at baseline and at least weekly during treatment. Patients should also be instructed to report any unexplained muscle pain, tenderness, or weakness. More frequent monitoring (every 2-3 days) is recommended for patients with renal impairment or those receiving concomitant medications that may increase the risk of myopathy.

How Should You Store Daptomycin Hikma?

Daptomycin Hikma vials should be stored in a refrigerator (2°C to 8°C) in the original packaging. Once reconstituted, the solution should be used within 12 hours at room temperature or within 24 hours if stored in a refrigerator.

Proper storage of daptomycin is essential to maintain its stability and antimicrobial potency. The powder for solution for injection/infusion comes in single-use glass vials and must be handled according to specific guidelines to ensure that the medication remains effective and safe for patient use.

Unopened vials: Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Keep the vial in the outer carton to protect from light. Do not freeze. The shelf life of unopened vials is typically 3 years from the date of manufacture when stored under recommended conditions.

Reconstituted solution: Chemical and physical in-use stability has been demonstrated for up to 12 hours at 25°C (room temperature) or up to 24 hours at 2°C to 8°C (refrigerator). From a microbiological point of view, the product should be used immediately after reconstitution. If not used immediately, the storage times and conditions are the responsibility of the user and should not exceed the times stated above.

Diluted solution for infusion: The combined storage time (reconstituted solution in vial plus diluted solution in infusion bag) should not exceed 12 hours at 25°C or 24 hours at 2°C to 8°C. The diluted solution in the infusion bag is stable for 12 hours at room temperature.

As with all medications, keep daptomycin out of the sight and reach of children. Do not use this medicine after the expiry date stated on the carton and vial label. Do not throw away any medicines via wastewater or household waste — ask your pharmacist how to dispose of medicines you no longer use.

What Does Daptomycin Hikma Contain?

Each vial of Daptomycin Hikma contains 350 mg of daptomycin as the active substance. The only excipient is sodium hydroxide, used for pH adjustment. After reconstitution with 0.9% sodium chloride, the solution has a concentration of 50 mg/mL.

Daptomycin Hikma has a straightforward formulation designed for intravenous administration:

Active substance: Each vial contains 350 mg of daptomycin. After reconstitution with 7 mL of sodium chloride 9 mg/mL (0.9%) solution for injection, each mL of reconstituted solution contains 50 mg of daptomycin.

Excipient(s): Sodium hydroxide (for pH adjustment). This is a minimal excipient profile, which contributes to the low risk of excipient-related hypersensitivity reactions.

Physical description: Daptomycin Hikma is a pale yellow to light brown lyophilized (freeze-dried) powder in a clear glass vial. After reconstitution, the solution should be a clear, pale yellow to light brown liquid. The reconstituted solution should be inspected visually for particulate matter and discoloration before use. If particulate matter is present or the solution is discolored, it should not be used.

Reconstitution: The powder must be reconstituted with sodium chloride 9 mg/mL (0.9%) solution for injection only. Do not use bacteriostatic water or saline containing preservatives such as benzyl alcohol, as these may cause precipitation. The reconstitution process involves slowly adding 7 mL of 0.9% sodium chloride to the vial, then gently rotating the vial to wet the powder. Allow the vial to stand for 10 minutes, then gently rotate the vial for a few minutes until the powder is completely dissolved. Vigorous shaking should be avoided as it may cause the solution to foam.

Sodium content: This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e., essentially sodium-free. This is relevant information for patients on a controlled sodium diet.

Frequently Asked Questions About Daptomycin Hikma